OSSIO
Intelligent Bone Implant Technology
Company Overview
Snapshot
Founded in July 2014 by Orahn Preiss-Bloom, OSSIO operates with 51–200 employees and has raised a total of $90.06 million across four disclosed funding rounds from 7 investors. In February 2026, the company secured debt financing, demonstrating continued investor confidence in its innovative orthopedic solutions.
Business overview
OSSIO is an orthopedic company that provides an innovative alternative to traditional metal implants within the orthopedic fixation market. Its core technology, OSSIOfiber, is a biofriendly implant material designed to be stronger than cortical bone while fully integrating into native anatomy without adverse inflammation, leaving nothing permanent behind. The company's proprietary technology can be adapted for numerous surgical applications and utilizes existing reimbursement and surgical techniques. OSSIO primarily serves the healthcare industry, targeting surgeons, doctors, and hospitals with its medical products and technologies.
Strategic signal
In December 2024, OSSIO successfully raised $27.6 million to accelerate its commercial engine, signaling strong market demand for its bio-integrative fixation technology. This funding round, led by Questa Capital, indicates investor validation of OSSIO's growth trajectory and its ability to expand patient access to its OSSIOfiber implants, positioning the company for significant commercial expansion in the orthopedic market.
Company Intelligence Q&A
- What was OSSIO's most recent funding activity?
- In February 2026, OSSIO secured debt financing, indicating ongoing financial support for its operations and growth initiatives.
- Which investors participated in the December 2024 funding round?
- In December 2024, OSSIO raised $27.6 million in a round led by Questa Capital, with participation from.
- When did OSSIO launch its OSSIOfiber Bone Pin for Hammertoe Correction in the U.S.?
- OSSIO announced the U.S. launch and first commercial use of its OSSIOfiber Bone Pin for Hammertoe Correction in May 2019.
- What significant regulatory milestone did OSSIO achieve in March 2022?
- In March 2022, OSSIO achieved its third FDA clearance in four months for OSSIOfiber implants, preparing to expand patient access to its bio-integrative orthopedic fixation technology portfolio.
- When did OSSIO receive the Frost & Sullivan New Product Innovation Award?
- OSSIO received the Frost & Sullivan New Product Innovation Award for its OSSIOfiber Intelligent Bone Regeneration Technology in June 2019.